https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19262
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19262
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADGlecaprevir / Pibrentasvir may inhibit CYP 3A4 and OATP1B1 and increase the plasma concentration of Lovastatin.
–
–
–
Possible increased risk of HMG CoA inhibitor toxicity.
Increased risk of myopathy and rhabdomyolysis.
Avoid association. Choose an alternative.
–
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
–
| Reference number |
|---|
| # patients |
| HCV |
| Dose |
| Frequency |
| Cmax |
| AUC |
| 3373 |
|---|
| 12 |
| - |
| 300/120 mg |
| QD |
| 3373 |
|---|
| 12 |
| - |
| 10 mg |
| QD |
| ± 0% * |
| + 70% * |
Ref #3373 : * Lovastatin acid (metabolite) AUC +310% (4.1x) and Cmax +473% (5.7x).
No significant changes in glecaprevir or pibrentasvir concentrations.